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The rational design of linear peptides that assemble controllably and predictably in water is challenging.
Short sequences must encode unique target structures and avoid alternative states. However, the non-
covalent forces that stabilize and discriminate between states are weak. Nonetheless, for a-helical
coiled-coil assemblies considerable progress has been made in rational de novo design. In these,
sequence repeats of nominally hydrophobic (h) and polar (p) residues, hpphppp, direct the assembly of
amphipathic helices into dimeric to tetrameric bundles. Expanding this pattern to hpphhph can produce
larger a-helical barrels. Here, we show that pentameric to nonameric barrels are accessed by varying the
residue at one of the h sites. In peptides with four L/I–K–E–I–A–x–Z repeats, decreasing the size of Z
from threonine to serine to alanine to glycine gives progressively larger oligomers. X-ray crystal
structures of the resulting a-helical barrels rationalize this: side chains at Z point directly into the helical
interfaces, and smaller residues allow closer helix contacts and larger assemblies.Introduction
Most commonly, natural coiled-coil (CC) peptides form dimers,
trimers and tetramers with consolidated hydrophobic cores.1,2
Control over oligomeric state is achieved by different combi-
nations of mainly isoleucine (Ile, I) and leucine (Leu, L) residues
in the core.3,4 Larger oligomers are rare in nature.5,6 Interest-
ingly, some of these larger structures are a-helical barrels
(aHBs) with accessible central channels making them appealing
scaffolds for functional design, e.g. binding, catalysis, delivery,
and transport.7–13 Variants of a natural dimer and de novo
tetramer serendipitously form heptameric and hexameric
aHBs, respectively.14,15 To automate the design of aHBs, we have
developed computational-design tools to deliver 5-, 6- or 7-helix
aHBs.16 These oligomers can be rationalized retrospectively to
advance further sequence-to-structure relationships for CC
design.
Most aHBs are Type-2 CCs based on hpphhph sequence
repeats, labelled abcdefg (Fig. 1).17 Typically, aHBs have L/
IxxIAxA repeats; i.e., a ¼ Leu or Ile and d ¼ Ile. b-Branched, Cantock's Close, Bristol BS8 1TS, UK.
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Bayreuth, Universitätsstraße 30, 95447
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the Royal Society of Chemistryresidues at d are particularly important for maintaining open
aHBs.18 The hexameric and heptameric aHBs (CC-Hex2 and CC-
Hept, systematically named CC-Type2-(SgLaId)4 and CC-Type2-
(AgLaId)4) have a ¼ Leu, d ¼ Ile and e ¼ alanine (Ala, A), but
differ at g, which is Ala in the heptamer and the slightly larger
serine (Ser, S) in the hexamer (Table 1). Another variant, CC-
Pent (CC-Type2-(IgLaIdEe)4) has Ile at g, although it differs
from the other examples having e ¼ glutamic acid (Glu, E).16 A
second series with all-Ile cores (a ¼ d ¼ Ile) has been charac-
terized.16,18 In these, another hexamer, CC-Hex3 (CC-Type2-(Sg-
IaId)4), follows the design rules above (Table 1);16 and a peptide
with Ala at g (CC-Type2-(AgIaId)4) forms an octamer when crys-
tallized in the presence of isopropanol.18
These previously described aHBs show a trend: increasing
the size of side chains at g decreases the oligomer state formed.
Therefore, we reasoned that a series of minimal changes, solelyFig. 1 (A and B) Type-N (A) and Type-2 (B) CC interfaces. The g
position is highlighted in the Type-2 interface. (C) Side-chain struc-
tures of glycine, alanine, serine and threonine.
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Table 1 Sequences of de novo aHBs and summary of biophysical characterizationa
Heptad repeat (abcdefg) Systematic name BUDE oligomer score DPH KD (mM) XRD aHB oligomeric state(s)
AUC
SV SE
LKEIAxT CC-Type2-(TgLaId)4 5 6.8  1.3 5 4.8 4.8
IKEIAxT CC-Type2-(TgIaId)4 5 0.84  0.19 5 5.4 5.2
LKEIAxS16 CC-Type2-(SgLaId)4 6 1.6  0.2 6 5.7 6.5
IKEIAxS16 CC-Type2-(SgIaId)4 6 3.8  0.8 6 6.2 6.1
LKEIAxA16 CC-Type2-(AgLaId)4 7 1.3  0.3 7 6.9 7.0
IKEIAxA16,18 CC-Type2-(AgIaId)4 6 2.2  0.3 8 6.1 5.7
LKEIAxG CC-Type2-(GgLaId)4 9 0.076  0.0065 9 (& collapsed 6) 6.5 6.3
IKEIAxG CC-Type2-(GgIaId)4 8 0.66  0.12 6 & 7 5.0 5.1
a BUDE: Bristol University Docking Engine. DPH: diphenylhexatriene. XRD: X-ray diffraction. AUC: analytical ultracentrifugation. SV: sedimentation
velocity. SE: sedimentation equilibrium.






















































































View Article Onlineat the g position—i.e., at Z in L/IxxIAxZ repeats—might direct
oligomeric state systematically and reliably.
Specically, we considered the addition of a single heavy
atom (C or O) to the side chain through the series glycine (Gly,
G), Ala, Ser and threonine (Thr, T) (Fig. 1C). Our aim was to
make a series of peptides with minimal changes to give a robust
family of aHBs with tuneable oligomeric states for applications
in synthetic biology and protein design.13 N.B. To maximise
further uses of the peptide assemblies, we avoided larger
hydrophobic residues at g, e.g. valine, as our experience is that
these can lead to difficulties in purication. We also avoided
cysteine because of potential issues with redox chemistry and to
reserve it for introducing function in follow-on studies.11,19,20Fig. 2 Solution-phase biophysical characterization of Gly@g (right)
and Thr@g (left) peptides. (A) CD spectra at 20 C. (B) Thermal dena-
turation following the CD signal at 222 nm (MRE222). (C) Saturation
binding curves with DPH. Key: CC-Type2-(TgLaId)4 (red), CC-Type2-
(TgIaId)4 (dark red, dashed), CC-Type2-(GgLaId)4 (blue) and CC-Type2-
(GgIaId)4 (navy, dashed). Conditions: (A and B) 10 mMpeptide. (C) 0–300
mM peptide, 1 mM DPH, 5% v/v DMSO. All experiments were performed
in phosphate buffered saline at pH 7.4 (PBS; 8.2 mM Na2HPO4, 1.8 mM
KH2PO4, 137 mM NaCl, 2.4 mM KCl).Results and discussion
To supplement foregoing designs with Ser and Ala at g, we
designed four peptides with Gly or Thr at this position; i.e., CC-
Type2-(GgLaId)4, CC-Type2-(GgIaId)4, CC-Type2-(TgLaId)4 and CC-
Type2-(TgIaId)4, Tables 1 and S2.† For simplicity, we refer to
these as Gly@g and Thr@g peptides. Our hypothesis was that
these should direct larger and smaller oligomers, respectively.
We built and optimized parametric models for Gly@g and
Thr@g in ISAMBARD.21 The sequences were modelled as
parallel aHBs of oligomer state 5 to 10, and scored using
BUDE22,23 (Table S3†). For the historical designs, the most-
favoured states were indeed those observed experimentally,16
the exception being CC-Type2-(AgIaId)4, which predicted as
a hexamer as observed in solution, but crystallized as an
octamer.18 Encouragingly, the new Thr@g sequences consis-
tently scored best as pentamers: for the a ¼ d ¼ Ile variant the
pentameric assembly was favoured outright; while the a ¼ Leu,
d ¼ Ile variant scored equally well as pentamer or hexamer.
Conversely, both Gly variants scored more favourably as larger
oligomeric states: the a¼ d¼ Ile variant as an octamer; and a¼
Leu, d ¼ Ile as a nonamer. Although, there was less discrimi-
nation between models for the Gly@g sequences than for
Thr@g, Fig. S1.† Thus, modelling supports the hypothesis that
oligomeric states of Type-2 CCs can be tuned by side chains at g.
The Gly@g and Thr@g peptides were synthesized, puried
by HPLC, and conrmed by mass spectrometry (Fig. S2–S8†).6924 | Chem. Sci., 2021, 12, 6923–6928Circular dichroism (CD) spectroscopy indicated that all four
peptides were a helical at low mM concentrations, Fig. 2A. CD
spectra recorded at increasing temperatures showed that both
Thr@g variants were hyperthermostable, Fig. 2B. Whereas, the
Gly@g variant with a ¼ Leu, d ¼ Ile had the beginnings of
a thermal unfolding curve consistent with the anticipated
destabilizing effect of Gly on a-helical structures.24–26 The Gly@g
variant with a ¼ d ¼ Ile unfolded at 38 C and did not fully
refold on cooling. Indeed, peptide sequences with a ¼ d ¼ Ile
are more unstable than their a ¼ Leu, d ¼ Ile counterparts.
Whilst b-branched residues like Ile clearly impart oligomer-© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 3 X-ray crystal structures for pentameric through to nonameric aHBs. (Left to right) CC-Type2-(TgLaId)4 (red, PDB 7BAS), CC-Type2-(TgIaId)4
(dark red, PDB 7BAU), CC-Type2-(SgLaId)4 (orange, PDB 4PN9), CC-Type2-(AgLaId)4 (yellow, PDB 4PNA), CC-Type2-(AgIaId)4 (green, PDB 6G67)
and CC-Type2-(GgLaId)4 (blue, PDB 7BIM).‡
1
Fig. 4 Structures of Gly@g variants. (A and B) Orthogonal views of the
collapsed hexameric-form of CC-Type2-(GgLaId)4 (PDB 7A1T). (C and






















































































View Article Onlinestate specicity in CC systems,3,4,18 we posit that this may be at
the expense of some loss in overall thermal stability.
Next, dye-binding assays were used to assess the presence of
accessible channels, Fig. 2C and S9† and Table 1. Binding of
diphenylhexatriene (DPH) is a reliable indicator that CC
peptides form aHBs in solution with a 1 : 1 correlation with X-
ray crystal structures.16,18 All four new peptides bound DPH
consistent with the formation of aHBs.
We determined X-ray protein crystal structures for all Gly@g
and Thr@g variants. As predicted, the Thr@g peptides formed
parallel pentamers (Fig. 3 and Tables S4 and S5†). Comparison
with the foregoing computationally designed pentamer, CC-
Type2-(IgLaIdEe)4,16 revealed similar CC parameters for the
structures. Signicantly, Thr@g with a ¼ d ¼ Ile has a wider
channel ofz9A than previous designs (z7A), which increases
the scope to functionalize this variant.
The Gly@g peptide with a ¼ Leu, d ¼ Ile crystallized in two
forms. Gratifyingly, one was an all-parallel nonamer, which is
a new aHB with an exceptionally large channel of diameter
z9.5–11.5A, Fig. 3 (Table S4†). Attempts to model solvent into
density observed in the channel were inconsistent. Therefore,
representative solvent molecules were included where they
matched the density; though these did not make any stabilizing
contacts with protein. Although there are natural nonameric
protein assemblies,27,28 this is the rst stand-alone, water-
soluble a-helical CC of this size. The second crystal form
revealed a collapsed C2-symmetric 6-helix bundle (Fig. 4A and
B, Table S4†). This was surprising, as the b-branched Ile resi-
dues at d would be expected to prevent collapse.18 We posit that
the small size of Gly relaxes this design rule allowing access to
other nearby regions of the CC free-energy landscape.29
Gly@g with a ¼ d¼ Ile also crystallized in two forms (Fig. 4C
and D, Table S5†), However, both solved as aHBs; namely,
a hexamer and a heptamer. Thus, b-branched Ile at both a and
d maintains the open assembly18 even with Gly residues at g.
Although a larger oligomer was predicted in silico, the© 2021 The Author(s). Published by the Royal Society of Chemistrycalculated internal energies for Gly@g were similar for the
different oligomers (Fig. S1†).
Because of the apparent structural duality with Gly@g, we
examined the oligomeric states of all peptides in solution by
analytical ultracentrifugation (AUC; Table 1, Fig. S10–S13†).
Both sedimentation velocity (SV) and sedimentation equilib-
rium (SE) measurements for the Thr@g variants returned pen-
tameric molecular weights consistent with the X-ray crystal
structures. Indeed, for the pentamers through heptamers for
these and previous designs, the correlation between the
solution-phase and crystal-state oligomers was good, Table 1.
However, where larger oligomers (octamer18 and nonamer)
were observed in crystals, smaller oligomers were consistently
observed in solution, Table 1. This suggests that the solutionD) The hexameric (C) and heptameric (D) form of CC-Type2-(GgIaId)4
(PDB 7BAT & 7BAW).‡
Chem. Sci., 2021, 12, 6923–6928 | 6925
Fig. 5 Analysis of pentameric to nonameric aHBs. (A and B) Cross-
sections through CC-Type2-(TgIaId)4 (red) and CC-Type2-(GgLaId)4
(blue) showing the geometry of residues at g (black and pink,
respectively). (C and D) Knobs-into-holes interaction showing how
these residues (black) contribute to a d0-1-g0-1-a0-d0 hole when Ile is the
knob residue (blue) (C); and when the Thr at the g position is a knob
residue (D). (E) Interhelical distances in the aHBs with Thr (red), Ser
(orange), Ala (yellow) and Gly (blue) at g. Errors are the standard
deviation of measurements from the central heptads of each structure.






















































































View Article Onlinestates are the dominant species, and that the higher oligomers
observed by X-ray crystallography are meta-stable. This is
consistent with smaller oligomers being entropically favoured.
In addition, the crystallization conditions for the octamer and
nonamer contained isopropanol. This increases the hydropho-
bicity of the bulk solvent, which potentially supports larger,
hydrophobic pores that would otherwise be energetically
unfavourable.29 Nevertheless, these are legitimate states to
consider as they are clearly accessible on the CC free-energy
landscape.
Summarizing these data, Type-2 CC peptides with sequence
repeats LppIApZ and Z ¼ Thr, Ser, or Ala, form pentameric,
hexameric, and heptameric aHBs, respectively. Adding Gly to
the series accesses a nonameric open barrel, but only in the
crystal state. Similarly, an IppIApA peptide forms an octamer in
the crystal state.18 These X-ray crystal structures enabled us to
examine the structural transitions in detail.
In all of the structures, the a and d residues contribute both
to the lumens and to interactions between neighbouring
helices. SOCKET30,31 analysis revealed that residues at a form
knobs that t into holes made by d0-1-g0-1-a0-d0 of a neighbouring
helix.32 Thus, these knobs are complemented by interactions
formed by the residues at g0-1 varied herein. The Ca-to-Cb bond
vectors of side chains at g point directly towards the adjacent
helix, Fig. 5A–D. In classical CCs, this is called perpendicular
packing, and it restricts how close the helices can
approach.3,32,33 Thus, mutations at g might be expected to
inuence the quaternary structure. The changes made in the‡ X-ray crystal structures for CC-Type2-(TgLaId)4-W19BrPhe,
CC-Type2-(TgIaId)4-W19BrPhe, CC-Type2-(GgLaId)4, CC-Type2-(GgLaId)4-W19BrPhe
and CC-Type2-(GgIaId)4 are available from the Protein Data Bank. Accession
codes: 7A1T, 7BAS, 7BAT, 7BAU, 7BAV, 7BAW & 7BIM.
6926 | Chem. Sci., 2021, 12, 6923–6928Gly/Ala/Ser/Thr series progressively add a single heavy
atom to that side chain: Gly (0 heavy atoms)/Ala (1)/Ser
(2)/Thr (3), Fig. 1C. It is gratifying, but still surprising, that
this leads to unitary changes in oligomer state, at least for the
Ala, Ser, and Thr variants. This is manifest in adjacent helix–
helix distances through the series, Fig. 5E. The average distance
increases from 8.0 0.1A in the Gly@g nonamer to 10.4 0.1A
in the Thr@g pentamer. Thus, through the series, neighbouring
helices are pushed apart effectively expelling helices from the
assembly.
The judicious placement of Gly may prove useful in designing
aHBs to unlock previously unseen architectures. However, using
Gly presents challenges that must be met to allow its full exploi-
tation. The rst challenge is incorporating multistate design into
aHBs, i.e. considering multiple conformations and/or assemblies
that may become accessible in the CC free-energy landscape.29 This
approach is being applied to other systems.34–36 It is tractable to
model many possible Type-2 aHBs to direct computational
design.16 However, this becomes difficult with increasing off-target
states, e.g. collapsed and anti-parallel structures. The second
challenge is to stabilize the larger, but clearly accessible, oligomer
states in solution. One possibility would be to introduce networks
of polar residues to reduce the penalty of all-hydrophobic chan-
nels.37 The hexameric and heptameric assemblies of CC-Type2-
(GgIaId)4 imply that, whilst Gly@g is necessary to access larger
states, it is not the only factor that dictates oligomer state of the
helical assembly. De novo aHBs have proved useful in functional
protein design.11–13 Reliably accessing scaffolds with signicantly
larger pores systematically and with minimal changes in primary
sequence, would expand the scope for this and future applications.Conclusions
We have combined rational design, computational modelling,
and structural biology for a series of a-helical barrels (aHBs)
with mutations from Gly/Ala/Ser/Thr at all g sites of
a coiled-coil (CC) sequence repeat. Minimal and stepwise
changes in size of the residue at these sites, combined with Leu/
Ile at a and Ile at d, control the oligomeric state of the assembly.
This expands the range of aHBs that can be designed system-
atically from pentamer (with Thr at g) to a nonamer (with Gly at
g). Inspection of X-ray crystal structures rationalizes the role of
side-chain bulk at g in dictating inter-helical packing distance,
angles, and, thus, oligomeric state. CC-Type2-(GgLaId)4 is the
rst example of a stand-alone nonameric CC. However, it
appears that high oligomeric states (such as 8 and 9) are on the
edge of what is possible for such ‘Type-2’ CC sequences as they
are not favoured in solution.16,18,38–40 Nonetheless, the X-ray
crystal structures show that they are accessible. The rarity of
such assemblies in nature6,17,27,28 and their potential as scaffolds
for functional de novo design makes these large aHBs tanta-
lizing targets for design. For example, de novo designed and
engineered aHBs have already proven useful in constructing
peptide nanotubes,8,9,12 peptide-based switches,10,29 a rudimen-
tary catalyst,11 membrane-spanning ion-channels41 and small-
molecule receptors.13© 2021 The Author(s). Published by the Royal Society of Chemistry
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